OXIS International Reports 2012 Year End Revenue Exceeds $340,000.

OXIS International, Inc., (OTCBB:OXIS) (Paris:OXI) today announced revenue for 2012 was in excess of $340,000. Fourth quarter revenue was up 55% from the prior quarter representing a $97,000 increase.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

BEVERLY HILLS, Calif. (PRWEB) January 31, 2013

OXIS International, Inc., (OTCBB:OXIS) (Paris:OXI) today announced revenue for 2012 was in excess of $340,000. Fourth quarter revenue was up 55% from the prior quarter representing a $97,000 increase.
“We’re were pleased with the initial test market in North America. Looking ahead to the first fiscal quarter of 2013 we’ll continue to ramp up earnings growth with our joint venture partner Engage:BDR,” said David Saloff, Oxis International CEO.
Prograce (http://www.prograceyou.com) and Reverge (http://www.revergeyou.com) have maintained consistent reorder rates following trials and continue to remain above 70%. The successful campaign can be partially attributed to the positive anti-aging effects of EGT™ the world’s only intelligent anti-oxidant. EGT™ is referred to as the "intelligent antioxidant" as it is the only anti-oxidant having a dedicated transport mechanism in the body to deliver it through the cell membrane and into the mitochondria, the energy producing area of the cell.    

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and Reactive Oxygen Species (ROS). The company holds the exclusive patent to manufacture EGT, which has received full GRAS (safety) approval. In addition the company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, including EGT(TM) (99% pure L-ergothioneine), known as the intelligent antioxidant.


Contact